Document is current
Any future updates will be listed below
-
Authors
Haile, Meseret T. https://orcid.org/0000-0002-5512-5260
Shukla, Anurag
Zhen, James https://orcid.org/0000-0002-5163-835X
Mather, Michael W. https://orcid.org/0000-0002-1062-0137
Bhatnagar, Suyash
Morrisey, Joanne M.
Zhang, Zhening
Vaidya, Akhil B. https://orcid.org/0000-0003-1063-5571
Ho, Chi-Min https://orcid.org/0000-0003-2132-7320
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (DP5OD029613, R01AI132508, R01AI154499)
- License Information
-
More Information
Article History
Received: 25 February 2025
Accepted: 26 September 2025
First Online: 20 October 2025
Competing interests
: M.T.H., A.S., J.Z., M.W.M., S.B., J.M.M., Z.Z., and C.M.H. report no competing interests. A.B.V. is listed as an inventor on US Patent 9,464,057. Applicants: MMV Medicines for Malaria Venture; University of Washington; Drexel University; Inventors: Jeremy Burrows, Matthew Wyvratt, Akhil Vaidya, Sandhya Kortagere, Erkang Fan, Arnab Chatterjee, Advait Nagle, Tomoyo Kato. “New Anti-Malarial Agents” (US Patent number 9,464,057). Patent granted: October 11, 2016. This patent covers compound PA21A092 used as an inhibitor for PfATP4.
